{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T06:29:01Z","timestamp":1768890541895,"version":"3.49.0"},"posted":{"date-parts":[[2025,6,16]]},"group-title":"In Review","reference-count":46,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T00:00:00Z","timestamp":1750032000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,6,4]]},"abstract":"<title>Abstract<\/title>\n                <p>There has been marked improvement in the clinical outcome of triple-negative breast cancer (TNBC) with the use of immune checkpoint blockade (ICB) although serious immune-related adverse effects are not uncommon. Unlike TNBC, ER\u03b1\u2009+\u2009breast tumors are largely unresponsive to ICB. Here we demonstrate defective priming by cross-presenting conventional dendritic cells (cDCs) and a blunted response to ICB in ER\u03b1\u2009+\u2009mouse mammary tumors compared to TNBC. Systemic administration of an agonistic CD40 antibody (aCD40) induced T cell proliferation and activation in tumor-draining lymph nodes and attracted effector T cells to the tumor bed from the periphery. This effect was largely due to activation, maturation and migration of type 1 conventional dendritic cells (cDC1s). aCD40 alone slowed tumor growth in ER\u03b1\u2009+\u2009tumors but its combination with ICB cured tumor-bearing mice, accomplishing a \u201cvaccine effect\u201d and the immune-mediated rejection of tumor rechallenge. The anti-tumor effect of aCD40 effect was cDC1 and CD8\u2009+\u2009T cell-dependent, whereas the rejection of secondary tumor rechallenge in cured mice required CD4\u2009+\u2009T cells. Importantly, intra-tumoral administration of aCD40 combined with systemic or intra-tumoral ICB \u2013 to mimic neoadjuvant therapeutic approaches\u2014induced complete regressions of both treated and distant tumors. These findings indicate that aCD40 achieves DC activation required for the response to immunotherapy in ER\u03b1\u2009+\u2009tumors and further supports intra-tumoral administration of both aCD40 and ICB as an effective treatment that might limit systemic exposure and lower risk of immune-related toxicity.<\/p>","DOI":"10.21203\/rs.3.rs-6823527\/v1","type":"posted-content","created":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T04:35:43Z","timestamp":1750048543000},"source":"Crossref","is-referenced-by-count":0,"title":["CD40 agonism enhances immune checkpoint blockade and generates immunologic memory via CD4+ T cells in ER\u03b1+ mammary tumors"],"prefix":"10.21203","author":[{"given":"Casey","family":"Lam","sequence":"first","affiliation":[{"name":"University of Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivia","family":"Lanchoney","sequence":"additional","affiliation":[{"name":"University of Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vishnu","family":"Maddipatla","sequence":"additional","affiliation":[{"name":"University of Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nune","family":"Markosyan","sequence":"additional","affiliation":[{"name":"University of Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikhil","family":"Joshi","sequence":"additional","affiliation":[{"name":"University of Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Courtney Ray","family":"Fofana","sequence":"additional","affiliation":[{"name":"University of Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan","family":"Zeng","sequence":"additional","affiliation":[{"name":"University of Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald P.","family":"DeMatteo","sequence":"additional","affiliation":[{"name":"University of Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert H.","family":"Vonderheide","sequence":"additional","affiliation":[{"name":"University of Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer Q.","family":"Zhang","sequence":"additional","affiliation":[{"name":"University of Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel RL","year":"2024","unstructured":"Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024. CA A Cancer J Clinicians 74, 12\u201349 (2024).","journal-title":"CA A Cancer J Clinicians"},{"key":"ref2","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju055","article-title":"US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status","volume":"106","author":"Howlader N","year":"2014","unstructured":"Howlader, N. et al. US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status. JNCI: Journal of the National Cancer Institute 106, (2014).","journal-title":"JNCI: Journal of the National Cancer Institute"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","article-title":"20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years","volume":"377","author":"Pan H","year":"2017","unstructured":"Pan, H. et al. 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. N Engl J Med 377, 1836\u20131846 (2017).","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1146\/annurev-med-070909-182917","article-title":"Mechanisms of Endocrine Resistance in Breast Cancer","volume":"62","author":"Osborne CK","year":"2011","unstructured":"Osborne, C. K. & Schiff, R. Mechanisms of Endocrine Resistance in Breast Cancer. Annu. Rev. Med. 62, 233\u2013247 (2011).","journal-title":"Annu. Rev. Med."},{"key":"ref5","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrc3920","article-title":"Mechanisms of aromatase inhibitor resistance","volume":"15","author":"Ma CX","year":"2015","unstructured":"Ma, C. X., Reinert, T., Chmielewska, I. & Ellis, M. J. Mechanisms of aromatase inhibitor resistance. Nat Rev Cancer 15, 261\u2013275 (2015).","journal-title":"Nat Rev Cancer"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar P","year":"2014","unstructured":"Cortazar, P. et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. The Lancet 384, 164\u2013172 (2014).","journal-title":"The Lancet"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1001\/jamaoncol.2018.7147","article-title":"Current Landscape of Immunotherapy in Breast Cancer: A Review","volume":"5","author":"Adams S","year":"2019","unstructured":"Adams, S. et al. Current Landscape of Immunotherapy in Breast Cancer: A Review. JAMA Oncol 5, 1205 (2019).","journal-title":"JAMA Oncol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer","volume":"387","author":"Cortes J","year":"2022","unstructured":"Cortes, J. et al. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. N Engl J Med 387, 217\u2013226 (2022).","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer","volume":"379","author":"Schmid P","year":"2018","unstructured":"Schmid, P. et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med 379, 2108\u20132121 (2018).","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","article-title":"Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer","volume":"391","author":"Schmid P","year":"2024","unstructured":"Schmid, P. et al. Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer. N Engl J Med 391, 1981\u20131991 (2024).","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s10549-017-4537-5","article-title":"Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study","volume":"167","author":"Dirix LY","year":"2018","unstructured":"Dirix, L. Y. et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. Breast Cancer Res Treat 167, 671\u2013686 (2018).","journal-title":"Breast Cancer Res Treat"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1158\/1078-0432.CCR-17-3452","article-title":"Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor\u2013Positive\/Human Epidermal Growth Factor Receptor 2\u2013Negative Advanced Breast Cancer","volume":"24","author":"Rugo HS","year":"2018","unstructured":"Rugo, H. S. et al. Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor\u2013Positive\/Human Epidermal Growth Factor Receptor 2\u2013Negative Advanced Breast Cancer. Clinical Cancer Research 24, 2804\u20132811 (2018).","journal-title":"Clinical Cancer Research"},{"key":"ref13","author":"Loi S","year":"2013","unstructured":"Loi, S. et al. Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02\u201398. JCO 31, 860\u2013867 (2013)."},{"key":"ref14","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","article-title":"Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy","volume":"19","author":"Denkert C","year":"2018","unstructured":"Denkert, C. et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. The Lancet Oncology 19, 40\u201350 (2018).","journal-title":"The Lancet Oncology"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein RM","year":"2019","unstructured":"Samstein, R. M. et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet 51, 202\u2013206 (2019).","journal-title":"Nat Genet"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S1470-2045(19)30689-8","article-title":"Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"21","author":"Schmid P","year":"2020","unstructured":"Schmid, P. et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology 21, 44\u201359 (2020).","journal-title":"The Lancet Oncology"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes J","year":"2020","unstructured":"Cortes, J. et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. The Lancet 396, 1817\u20131828 (2020).","journal-title":"The Lancet"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for Early Triple-Negative Breast Cancer","volume":"382","author":"Schmid P","year":"2020","unstructured":"Schmid, P. et al. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med 382, 810\u2013821 (2020).","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1600-065X.2009.00782.x","article-title":"Molecular mechanism and function of CD40\/CD40L engagement in the immune system","volume":"229","author":"Elgueta R","year":"2009","unstructured":"Elgueta, R. et al. Molecular mechanism and function of CD40\/CD40L engagement in the immune system. Immunological Reviews 229, 152\u2013172 (2009).","journal-title":"Immunological Reviews"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1146\/annurev-med-062518-045435","article-title":"CD40 Agonist Antibodies in Cancer Immunotherapy","volume":"71","author":"Vonderheide RH","year":"2020","unstructured":"Vonderheide, R. H. CD40 Agonist Antibodies in Cancer Immunotherapy. Annu. Rev. Med. 71, 47\u201358 (2020).","journal-title":"Annu. Rev. Med."},{"key":"ref21","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1146\/annurev-med-062518-045435","article-title":"CD40 Agonist Antibodies in Cancer Immunotherapy","volume":"71","author":"Vonderheide RH","year":"2020","unstructured":"Vonderheide, R. H. CD40 Agonist Antibodies in Cancer Immunotherapy. Annu. Rev. Med. 71, 47\u201358 (2020).","journal-title":"Annu. Rev. Med."},{"key":"ref22","doi-asserted-by":"crossref","first-page":"e20190673","DOI":"10.1084\/jem.20190673","article-title":"Type 1 conventional dendritic cells are systemically dysregulated early in pancreatic carcinogenesis","volume":"217","author":"Lin JH","year":"2020","unstructured":"Lin, J. H. et al. Type 1 conventional dendritic cells are systemically dysregulated early in pancreatic carcinogenesis. Journal of Experimental Medicine 217, e20190673 (2020).","journal-title":"Journal of Experimental Medicine"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.smim.2009.05.010","article-title":"The role of CD40 and CD154\/CD40L in dendritic cells","volume":"21","author":"Ma DY","year":"2009","unstructured":"Ma, D. Y. & Clark, E. A. The role of CD40 and CD154\/CD40L in dendritic cells. Seminars in Immunology 21, 265\u2013272 (2009).","journal-title":"Seminars in Immunology"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/jlb.67.1.2","article-title":"CD40-CD40 ligand","volume":"67","author":"Kooten C","year":"2000","unstructured":"Van Kooten, C. & Banchereau, J. CD40-CD40 ligand. Journal of Leukocyte Biology 67, 2\u201317 (2000).","journal-title":"Journal of Leukocyte Biology"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1158\/2326-6066.CIR-17-0345","article-title":"Macrophages and CD8\u2009+\u2009T Cells Mediate the Antitumor Efficacy of Combined CD40 Ligation and Imatinib Therapy in Gastrointestinal Stromal Tumors","volume":"6","author":"Zhang JQ","year":"2018","unstructured":"Zhang, J. Q. et al. Macrophages and CD8\u2009+\u2009T Cells Mediate the Antitumor Efficacy of Combined CD40 Ligation and Imatinib Therapy in Gastrointestinal Stromal Tumors. Cancer Immunology Research 6, 434\u2013447 (2018).","journal-title":"Cancer Immunology Research"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/31002","article-title":"M. T-cell help for cytotoxic T lymphocytes is mediated by CD40\u2013CD40L interactions","volume":"393","author":"Schoenberger SP","year":"1998","unstructured":"Schoenberger, S. P., Toes, R. E. M., Van Der Voort, E. I. H., Offringa, R. & Melief, C. J. M. T-cell help for cytotoxic T lymphocytes is mediated by CD40\u2013CD40L interactions. Nature 393, 480\u2013483 (1998).","journal-title":"Nature"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/30996","article-title":"Help for cytotoxic-T-cell responses is mediated by CD40 signalling","volume":"393","author":"Bennett SRM","year":"1998","unstructured":"Bennett, S. R. M. et al. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393, 478\u2013480 (1998).","journal-title":"Nature"},{"key":"ref28","author":"Morrison AH","year":"2020","unstructured":"Morrison, A. H., Diamond, M. S., Hay, C. A., Byrne, K. T. & Vonderheide, R. H. Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity. Proc. Natl. Acad. Sci. U.S.A. 117, 8022\u20138031 (2020)."},{"key":"ref29","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1158\/2326-6066.CIR-14-0215","article-title":"Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma","volume":"3","author":"Winograd R","year":"2015","unstructured":"Winograd, R. et al. Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma. Cancer Immunology Research 3, 399\u2013411 (2015).","journal-title":"Cancer Immunology Research"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"e1468956","DOI":"10.1080\/2162402X.2018.1468956","article-title":"Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma","volume":"7","author":"Bajor DL","year":"2018","unstructured":"Bajor, D. L. et al. Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma. OncoImmunology 7, e1468956 (2018).","journal-title":"OncoImmunology"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/s41591-022-01829-9","article-title":"Sotigalimab and\/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial","volume":"28","author":"Padr\u00f3n LJ","year":"2022","unstructured":"Padr\u00f3n, L. J. et al. Sotigalimab and\/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial. Nat Med 28, 1167\u20131177 (2022).","journal-title":"Nat Med"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S1470-2045(20)30532-5","article-title":"CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study","volume":"22","author":"O\u2019Hara MH","year":"2021","unstructured":"O\u2019Hara, M. H. et al. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. The Lancet Oncology 22, 118\u2013131 (2021).","journal-title":"The Lancet Oncology"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1470-2045(24)00263-8","article-title":"Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b\/2 study","volume":"25","author":"Laethem J-L","year":"2024","unstructured":"Van Laethem, J.-L. et al. Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b\/2 study. The Lancet Oncology 25, 853\u2013864 (2024).","journal-title":"The Lancet Oncology"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"e267","DOI":"10.1038\/oncsis.2016.65","article-title":"Constitutively activated PI3K accelerates tumor initiation and modifies histopathology of breast cancer","volume":"5","author":"Sheen MR","year":"2016","unstructured":"Sheen, M. R. et al. Constitutively activated PI3K accelerates tumor initiation and modifies histopathology of breast cancer. Oncogenesis 5, e267\u2013e267 (2016).","journal-title":"Oncogenesis"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"8074","DOI":"10.1002\/cam4.3295","article-title":"EO771, is it a well-characterized cell line for mouse mammary cancer model? Limit and uncertainty","volume":"9","author":"Naour A","year":"2020","unstructured":"Le Naour, A., Rossary, A. & Vasson, M. EO771, is it a well-characterized cell line for mouse mammary cancer model? Limit and uncertainty. Cancer Medicine 9, 8074\u20138085 (2020).","journal-title":"Cancer Medicine"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.cels.2019.08.009","article-title":"Neoantigen Dissimilarity to the Self-Proteome Predicts Immunogenicity and Response to Immune Checkpoint Blockade","volume":"9","author":"Richman LP","year":"2019","unstructured":"Richman, L. P., Vonderheide, R. H. & Rech, A. J. Neoantigen Dissimilarity to the Self-Proteome Predicts Immunogenicity and Response to Immune Checkpoint Blockade. Cell Systems 9, 375\u2013382.e4 (2019).","journal-title":"Cell Systems"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1158\/1078-0432.CCR-19-3507","article-title":"Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1\/L1 Blockade in Metastatic Triple-Negative Breast Cancer","volume":"26","author":"Barroso-Sousa R","year":"2020","unstructured":"Barroso-Sousa, R. et al. Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1\/L1 Blockade in Metastatic Triple-Negative Breast Cancer. Clinical Cancer Research 26, 2565\u20132572 (2020).","journal-title":"Clinical Cancer Research"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"5815","DOI":"10.3390\/cancers14235815","article-title":"Feasibility of Intratumoral Anti-PD1 as Treatment of Human Basal Cell Carcinoma: An Explorative Study with Adjuvant Ablative Fractional Laser","volume":"14","author":"Omland SH","year":"2022","unstructured":"Omland, S. H. et al. Feasibility of Intratumoral Anti-PD1 as Treatment of Human Basal Cell Carcinoma: An Explorative Study with Adjuvant Ablative Fractional Laser. Cancers 14, 5815 (2022).","journal-title":"Cancers"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1172\/JCI128562","article-title":"In situ vaccination with defined factors overcomes T cell exhaustion in distant tumors","volume":"129","author":"Khalil DN","year":"2019","unstructured":"Khalil, D. N. et al. In situ vaccination with defined factors overcomes T cell exhaustion in distant tumors. Journal of Clinical Investigation 129, 3435\u20133447 (2019).","journal-title":"Journal of Clinical Investigation"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1002\/ijc.32141","article-title":"First-in\u2010human study with intratumoral administration of a CD40 agonistic antibody, ADC\u20101013, in advanced solid malignancies","volume":"145","author":"Irenaeus SMM","year":"2019","unstructured":"Irenaeus, S. M. M. et al. First-in\u2010human study with intratumoral administration of a CD40 agonistic antibody, ADC\u20101013, in advanced solid malignancies. Intl Journal of Cancer 145, 1189\u20131199 (2019).","journal-title":"Intl Journal of Cancer"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/14737140.2017.1270208","article-title":"Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists","volume":"17","author":"Beatty GL","year":"2017","unstructured":"Beatty, G. L., Li, Y. & Long, K. B. Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists. Expert Review of Anticancer Therapy 17, 175\u2013186 (2017).","journal-title":"Expert Review of Anticancer Therapy"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"e137263","DOI":"10.1172\/jci.insight.137263","article-title":"H. CCL5 mediates CD40-driven CD4\u2009+\u2009T cell tumor infiltration and immunity","volume":"5","author":"Huffman AP","year":"2020","unstructured":"Huffman, A. P., Lin, J. H., Kim, S. I., Byrne, K. T. & Vonderheide, R. H. CCL5 mediates CD40-driven CD4\u2009+\u2009T cell tumor infiltration and immunity. JCI Insight 5, e137263 (2020).","journal-title":"JCI Insight"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.cytogfr.2013.03.001","article-title":"A myriad of functions and complex regulation of the CCR7\/CCL19\/CCL21 chemokine axis in the adaptive immune system","volume":"24","author":"Comerford I","year":"2013","unstructured":"Comerford, I. et al. A myriad of functions and complex regulation of the CCR7\/CCL19\/CCL21 chemokine axis in the adaptive immune system. Cytokine & Growth Factor Reviews 24, 269\u2013283 (2013).","journal-title":"Cytokine & Growth Factor Reviews"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ccell.2016.06.003","article-title":"Critical Role for CD103+\/CD141\u2009+\u2009Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma","volume":"30","author":"Roberts EW","year":"2016","unstructured":"Roberts, E. W. et al. Critical Role for CD103+\/CD141\u2009+\u2009Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma. Cancer Cell 30, 324\u2013336 (2016).","journal-title":"Cancer Cell"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41467-024-44787-1","article-title":"Tumour-retained activated CCR7\u2009+\u2009dendritic cells are heterogeneous and regulate local anti-tumour cytolytic activity","volume":"15","author":"Lee CYC","year":"2024","unstructured":"Lee, C. Y. C. et al. Tumour-retained activated CCR7\u2009+\u2009dendritic cells are heterogeneous and regulate local anti-tumour cytolytic activity. Nat Commun 15, 682 (2024).","journal-title":"Nat Commun"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/8426","article-title":"CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help","volume":"5","author":"French RR","year":"1999","unstructured":"French, R. R., Chan, H. T. C., Tutt, A. L. & Glennie, M. J. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat Med 5, 548\u2013553 (1999).","journal-title":"Nat Med"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-6823527\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-6823527\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T17:20:26Z","timestamp":1768843226000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-6823527\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,16]]},"references-count":46,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-6823527\/v1","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1038\/s41523-025-00889-7","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2025,6,16]]},"subtype":"preprint"}}